While these data confirm the connection between RTK inhibition and ultimate tumor prevention, the results also suggest that lapatinib may induce a broader impact on erbB-2/EGFR signaling beyond the canonical regulatory pathways. This evidence concerns the gene ERBB2 and neoplasm.